Table 4.
Study type | Study design | Preparations | Dose | Effects | Ref. |
---|---|---|---|---|---|
Rats exposed to nicotine | A. cepa oil | 100 mg/kg b.w., 21 days | Increased CAT and SOD activity in the lung tissue | [101] | |
Exp | Mice | Qt | — | Decreased superoxide radicals and LPO; lung morphological changes | [110] |
Swiss albino male mice | Qt | — | Lowered the lipid peroxide levels | [111] | |
Cell line NCI-H209 | Qt glucuronides | — | Qt glucuronides inhibited proliferation through G2/M arrest of the cell cycle and induced apoptosis via caspase-3 cascade in the human lung cancer cell line NCI-H209 | [99] | |
Cat fish | A. cepa extract | 1000 mg/ml | Antibacterial activity | [98] | |
Mice | Ethanol extract | 10 and 20 mg/ml | Antibacterial effect | [150] | |
Mesocestoides corti infection in BALB/c mice | Qt | 5.0–20.0 mg/kg, oral | Decreased peripheral blood eosinophilia and IgE hyperproduction | [135] | |
Clin | Lung cancer patients | A. cepa extracts | 10 g L−1 | Antiproliferative capacity; decreased mitotic indices | [98] |
Adenocarcinoma patients | Qt-rich food | — | Decreased lung cancer risk; upregulated GSTM1, GSTM2, GSTT2, and GSTP1; downregulated specific P450 genes | [102] | |
Lung cancer patients | Qt-rich food | mg/100 g | Decreased carcinogenesis-related miR-146, miR-26, and miR-17 families | [151] | |
DPT patients | Qt and QP | 5 g in 100 mL saline | Reduction of the disease manifestation | [115] | |
Cell line NCI-H209 | Qt glucuronides | — | Qt glucuronides inhibited proliferation through G2/M arrest of the cell cycle and induced apoptosis via caspase-3 cascade in the human lung cancer cell line NCI-H209 | [99] | |
Clinical study | A. cepa aqueous extract | — | Antibacterial effect on Gram-positive and Gram-negative bacteria; effect on A549 lung cancer cell lines | [100] | |
Virus-infected patients | Inhaled onion, garlic extract | — | Improved all respiratory symptoms | [107] | |
Clinical study | Vitamin C and Qt | 30 or 40 mg/kg, 4 days | Treatment of respiratory tract infections with COVID-19 | [112] | |
Clinical study | Qt and NAC, nebulized | 600 and 300 mg/mL for Qt and NAC | Decreased respiratory symptoms; antiviral in COVID-19 infection | [114] |
Ref.: references, Exp: experimental, and Clin: clinical.